16α-[¹⁸F]Fluoroestradiol is radiolabeled form of estradiol that allows whole-body, noninvasive evaluation of tissues expressing estrogen receptors (ER). It was the first receptor-targeted PET radiotracer for oncology and has been used as a research agent for several decades.[1] Recently, 16α-[¹⁸F]Fluoroestradiol has been increasingly used in clinics (under approved INDs, compassionate use programs) for the detection of metastatic ER-positive breast cancer.[2]
[1] Katzenellenbogen, J. A. The Quest for Improving the Management of Breast Cancer by Functional Imaging: The Discovery and Development of 16α-[18F]Fluoroestradiol (FES), a PET Radiotracer for the Estrogen Receptor, an Historical Review. Nucl. Med. Biol. 2021, 92, 24–37. [2] O’Brien S. R. et al. 18F-Fluoroestradiol: Current Applications and Future Directions. RadioGraphics 2023, 43, 3.
ABX offers the research grade (ABX prod. no. 1900) as well as the GMP (ABX prod. no. 1901) precursor and the reference standard (ABX prod. no. 1910).
ABX advanced biochemical compounds is a global frontrunner in radiopharmaceuticals, with a focus on positron emission tomography (PET) tracers. We develop and produce all compounds and components for any kind of radiotracer – from PET and SPECT precursors, PET reagent kits and cassettes, to complete radiopharmaceutical drug production in GMP environment.
Based in Radeberg, Germany, and founded in 1997, our team of about 400 employees is specialised in custom synthesis and manufacturing of precursors and peptides according to GMP for active pharmaceutical ingredients. Thanks to our expertise combined with bleeding edge equipment, we reach highest research, production, and quality standards.
ABX is the only service provider of radiopharmaceutical production with a complete and independent supply chain – from precursor or peptide to excipients and sterile disposables.
